Back to Search Start Over

First Dual AK/GSK-3β Allosteric Inhibitors Endowed with Antioxidant Properties as Multifunctional, Potential Neuroprotective Agents

Authors :
Alessandra Pecorelli
Stefania Butini
Lida Savi
Federico Focher
Margherita Brindisi
Gloria Alfano
Giulia Chemi
Giuseppe Valacchi
Paola Galatello
Erika Pambianchi
Simone Brogi
Giulia Compagnoni
Anna Ramunno
Giuseppe Campiani
Sandra Gemma
Giuseppe Biamonti
Brogi, Simone
Ramunno, Anna
Savi, Lida
Chemi, Giulia
Alfano, Gloria
Pecorelli, Alessandra
Pambianchi, Erika
Galatello, Paola
Compagnoni, Giulia
Focher, Federico
Biamonti, Giuseppe
Valacchi, Giuseppe
Butini, Stefania
Gemma, Sandra
Campiani, Giuseppe
Brindisi, Margherita
Publication Year :
2017

Abstract

The manuscript deals with the design, synthesis and biological evaluation of novel benzoxazinone-based and indole-based compounds as multifunctional neuroprotective agents. These compounds inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes. Computational analysis based on a molecular docking approach underlined the potential structural requirements for simultaneously targeting both proteins' allosteric sites. In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3β. For both our hit 4 and the best compounds of the series (5c,l and 6b) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32, undifferentiated and neuronal differentiated), by evaluating the protective effect of selected compounds against H2O2 cytotoxicity and reactive oxygen species (ROS) production. Results showed a strong efficacy of the tested compounds, even at the lower doses, in counteracting the induced oxidative stress (50 μM of H2O2) and in preventing ROS formation. In addition, the tested compounds did not show any cytotoxic effect determined by the LDH release, at the concentration range analyzed (from 0.1 to 50 μM). This study allowed the identification of compound 5l, as the first dual hAK/hGSK-3β inhibitor reported to date. Compound 5l, which behaves as an effective antioxidant, holds promise for the development of new series of potential therapeutic agents for the treatment of neurodegenerative diseases characterized by an innovative pharmacological profile.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....69c684da5bb8d35380834a100e6af981